Polar Capital Holdings Plc Sells 26,910 Shares of Mirum Pharmaceuticals, Inc. $MIRM

Polar Capital Holdings Plc decreased its stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 3.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 793,642 shares of the company’s stock after selling 26,910 shares during the period. Polar Capital Holdings Plc’s holdings in Mirum Pharmaceuticals were worth $62,690,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently made changes to their positions in MIRM. Cullen Frost Bankers Inc. acquired a new stake in Mirum Pharmaceuticals during the 4th quarter valued at approximately $30,000. Eurizon Capital SGR S.p.A. acquired a new position in shares of Mirum Pharmaceuticals in the 4th quarter worth approximately $32,000. CIBC Private Wealth Group LLC acquired a new position in shares of Mirum Pharmaceuticals in the 4th quarter worth approximately $32,000. Quantbot Technologies LP bought a new stake in shares of Mirum Pharmaceuticals in the 3rd quarter valued at $33,000. Finally, Comerica Bank increased its position in shares of Mirum Pharmaceuticals by 45.1% during the first quarter. Comerica Bank now owns 895 shares of the company’s stock worth $40,000 after buying an additional 278 shares during the period.

Insider Activity

In related news, CFO Eric Bjerkholt sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, June 8th. The stock was sold at an average price of $93.82, for a total transaction of $469,100.00. Following the transaction, the chief financial officer directly owned 44,788 shares of the company’s stock, valued at approximately $4,202,010.16. This represents a 10.04% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Christopher Peetz sold 30,000 shares of the stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $95.84, for a total value of $2,875,200.00. Following the completion of the transaction, the chief executive officer owned 194,309 shares in the company, valued at approximately $18,622,574.56. The trade was a 13.37% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 8.32% of the company’s stock.

Mirum Pharmaceuticals Stock Up 0.5%

Mirum Pharmaceuticals stock opened at $101.55 on Wednesday. The company has a market capitalization of $6.19 billion, a PE ratio of -7.46 and a beta of 0.50. Mirum Pharmaceuticals, Inc. has a 12-month low of $47.89 and a 12-month high of $114.99. The firm’s fifty day moving average is $98.17 and its 200 day moving average is $91.67. The company has a quick ratio of 1.99, a current ratio of 2.09 and a debt-to-equity ratio of 1.28.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its quarterly earnings results on Wednesday, May 6th. The company reported ($13.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.75) by ($12.68). Mirum Pharmaceuticals had a negative return on equity of 11.28% and a negative net margin of 140.24%.The company had revenue of $159.88 million during the quarter, compared to analyst estimates of $148.21 million. During the same quarter in the previous year, the business posted ($0.30) earnings per share. The company’s revenue for the quarter was up 43.3% compared to the same quarter last year. As a group, sell-side analysts predict that Mirum Pharmaceuticals, Inc. will post -2.01 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

MIRM has been the subject of a number of analyst reports. Royal Bank Of Canada lifted their target price on shares of Mirum Pharmaceuticals from $128.00 to $142.00 and gave the stock an “outperform” rating in a research note on Thursday, May 7th. Weiss Ratings upgraded Mirum Pharmaceuticals from a “sell (d-)” rating to a “sell (d)” rating in a report on Monday, June 8th. Raymond James Financial reissued a “strong-buy” rating and issued a $165.00 price objective on shares of Mirum Pharmaceuticals in a research report on Thursday, May 7th. Wolfe Research began coverage on Mirum Pharmaceuticals in a research note on Tuesday, May 19th. They issued an “outperform” rating and a $145.00 price objective on the stock. Finally, Stifel Nicolaus set a $136.00 target price on Mirum Pharmaceuticals in a research report on Thursday, May 7th. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $139.80.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.